Know exactly where radioligand therapy can be delivered — and how to get there first
Theranostix shows biopharma which European centres are ready to treat, who runs them, what they're trialling, and how to reach them — so you activate faster, select sites with confidence, and get therapy to more patients.
Trial data from ClinicalTrials.gov and CTIS. Figures reflect current coverage and grow continuously.
The molecule is the easy part. Getting it delivered is where launches stall.
You've run the trials and won the approval. Now the hard question lands on your desk: which European centres can actually treat patients — and how do you reach, qualify and activate them before a competitor does? Today, most teams answer it with spreadsheets, field-team hearsay and registry data that was never built for this.
You can't see who's ready to treat
Therapy beds, shielded rooms, dosimetry, trained staff — readiness varies centre by centre, and no commercial dataset captures it. You're guessing.
Site activation drags your launch
Every month spent identifying and qualifying centres is a month of stranded capacity — and patients who don't get treated.
Feasibility runs on assumptions
Trial site selection still leans on relationships and best guesses. Identification takes months, and some sites never enrol.
Competitor moves surface too late
In a field this fast and this well-funded, learning about a rival's trial or target after the fact costs you the white-space.
Global databases miss the ground
Citeline, IQVIA and the like tell you what's registered and where. They don't tell you which European centre can actually deliver therapy next month.
Every market starts from zero
Nine countries, six languages, fragmented systems. Building the picture country-by-country is slow, costly and never quite current.
The result is predictable: slower launches, capacity that sits idle, feasibility that overruns, and patients who wait — while the intelligence you need is scattered across registries, congresses and people who haven't met.
One screen that turns "we think" into "we know"
Picture opening a single view of the European theranostics landscape — and finding the answers your team currently spends months assembling, already there.
- You see the exact centres ready to deliver your isotope, ranked by readiness
- You know which 40 sites to activate first, and in what order, by market
- Feasibility shortlists take days, not months
- You spot a competitor's pipeline move the week it registers
- You reach the right clinicians, in their language, before launch
- You walk into the leadership review with a defensible plan, not a hunch
That's exactly why we built Theranostix
Theranostix is the operating picture of theranostics delivery in Europe — one independent, multilingual intelligence service that connects what's being developed to where it can actually be delivered. We turn public trial data and a living clinician community into decisions your commercial, medical and clinical teams can act on with confidence.
We map the landscape
Every RLT trial, target, isotope and sponsor in Europe — structured from ClinicalTrials.gov and CTIS, refreshed continuously.
We score the ground-truth
We rank the ~800 centres in our directory by real theranostics readiness and capability — the layer no global database has.
You act with confidence
Filter, score and export the view your team needs — to activate centres, select sites, track competitors and reach clinicians.
One intelligence hub, built for theranostics
Each capability stands alone or works together — and every team sees the slice that matters to them.
Trial cartography
RLT trials mapped by target (PSMA, SSTR2, FAP, GRPR…), isotope (Lu-177, Ac-225), phase, sponsor & country.
Centre readiness scoring
Our signature layer: ranks European centres by real readiness to deliver therapy.
Sponsor & pipeline mapping
See who's developing what, against which target, and how the pipeline shifts over time.
Reach, KOL & workforce signals
Engage the clinicians who treat — and read capacity gaps from live workforce demand.
Activate the right centres
Prioritise treatment-ready centres and sequence your launch by readiness and capacity.
Track the pipeline
See pipeline by target and sponsor; spot competitor moves and white-space early.
Run feasibility faster
Shorten site identification; target qualified centres by target, country and capability.
Intelligence you — and your compliance team — can stand behind
We know the first question your medical-legal and procurement teams will ask. Theranostix is built on public sources and aggregated, anonymised signals — never patient data. The clinician community behind our data stays free and editorially independent, which is exactly what keeps the intelligence credible.
- ✓ Public-source provenance (ClinicalTrials.gov, CTIS)
- ✓ No patient data, ever
- ✓ No pay-to-rank in the centre directory
- ✓ Sponsored content clearly labelled
- ✓ MDR / EFPIA-aware, GDPR-compliant
Built from the specialty, not above it
Founded by a practising nuclear-medicine specialist and powered by the Nucleascope community of physicians and technologists.
Complements your existing stack
We don't replace Citeline or IQVIA. We add the European, centre-level delivery layer they don't have.
Scales from one asset to a portfolio
Start with a single target and market on Explorer; grow to multi-country and enterprise as you do.
Questions you're probably asking
We already license a global trial database. Why add Theranostix?
Global databases tell you what's registered and where. They were never built to tell you which European centre can actually deliver radioligand therapy next quarter, how ready it is, or how to reach the team. Theranostix adds exactly that delivery layer — and sits alongside what you already use.
Is this compliant? Our medical-legal team is strict — rightly.
Yes. Theranostix is a B2B intelligence service sold to companies, not promotion to prescribers. It uses public sources and aggregated, anonymised signals, holds no patient data, and is MDR/EFPIA-aware and GDPR-compliant. We'll share the full methodology and security pack under NDA.
We're an emerging biotech with a small budget. Is this for us?
Especially. Our Explorer tier covers a single target or country for a single team, so you can answer your most urgent site-selection and competitive questions without an enterprise commitment — and a one-off custom report is an even lighter way in.
How current and credible is the data?
Trial data is drawn from ClinicalTrials.gov and CTIS and refreshed on a defined cadence; centre and readiness signals come from the continuously-maintained Nucleascope backbone, with human verification of high-stakes fields and a built-in corrections loop.
How fast can we get value?
A tailored walkthrough takes 30 minutes, a custom report a matter of weeks, and a license can be scoped and live without a lengthy procurement cycle. Most teams see the gap we fill within the first session.
"The operating picture of theranostics delivery in Europe — which centres can treat, who runs them, what they're trialling, and how to reach them — in one independent, multilingual intelligence service."
See what Theranostix can show you about your market
Book a 30-minute walkthrough tailored to your target, your countries and your team's decisions.